+44 20 8123 2220
info@marketpublishers.com

Leading Anti-Cancer Drugs and Associated Market 2013-2023

https://marketpublishers.com/r/LA0F1D356C7EN.html
Date: June 2013
Pages: 188
Price: US$ 2,635.00 (Single User License)
ID: LA0F1D356C7EN

Abstracts

Cancer treatments - here's your guide to R&D and sales potentials

Do you want to assess the future of cancer medicines? Visiongain's updated report gives you revenue predictions there from 2013, helping you stay ahead. You find financial data, R&D trends, opportunities, and outlooks.

In that work you see forecasted sales to 2023 at overall world market, submarket, product, and national level. You also assess emerging trends, technologies, and expected drugs.

You see what shapes that industry and find its revenue prospects

Discover, then, what the future holds for anti-cancer products. Read on to explore that industry and see what its future market could be worth.

Forecasts to 2023 and other analyses show you commercial potentials

Besides revenue forecasting to 2023, you find historical data, growth rates, and market shares. You assess quantitative and qualitative analysis, business news, outlooks, and developments (R&D). You also gain 114 tables, 47 charts, and three interviews.

Is finding data for cancer treatment a challenge? Our work lets you investigate the most promising and lucrative parts of applied oncology, helping you stay ahead in knowledge. That way, you reduce your risk of missing out. Finding data you need has just got easier.

+44 20 8123 2220
info@marketpublishers.com

Many opportunities remain for cancer-treating drugs. Now see how you can benefit your research, analyses, and decisions there.

The following sections show, then, how you benefit from our new investigation and analysis.

Discover outlooks for the world market and submarkets

Along with prediction of overall world market value to 2023, our report shows you revenue forecasting of four submarkets at world level:

Immunotherapies

Targeted therapies

Hormone-based agents

Chemotherapies.

Also our study discusses what stimulates and restrains business. That analysis helps you identify potential and find ways for your business to develop. Assess leading brands too.

See forecasts for the leading 25 cancer-treating drugs

How will leading drugs perform to 2023 at world level? Our study forecasts individual revenues of the top 25 anti-cancer agents, including these products:

Rituxan

Herceptin

Avastin

Gleevec

Revlimid

+44 20 8123 2220
info@marketpublishers.com

Alimta

Velcade.

There you discover how high sales can go, to 2023, finding drugs and years with highest predicted growth and revenues. You see what's happening, then, understanding trends, competition, challenges, and opportunities. Also, assess drugs approved from 2012 to 2013.

You find geographical revenue predictions too.

Leading national markets - where lie highest revenues and growth?

Developments worldwide expand the cancer drugs market, especially rising demand for medicines in emerging countries. China, India, Russia, and Brazil underpin revenue growth.

In developed and developing countries, opportunities for pharma companies will occur from 2013. See where and how.

Our analyses show you individual revenue forecasts to 2023 for 11 national markets:

US

Japan

Germany, France, UK, Italy, and Spain (EU5)

Brazil, Russia, India, and China (BRIC).

You find potential. Our analyses show growth will occur in established pharma markets and in developing countries. In particular, drug launches from 2013 to 2023 will change medical prescribing and the commercial landscape.

Research and development - assess innovation, trends, and possibilities

What's happening in oncological R&D? You see trends for treating these cancers:

+44 20 8123 2220
info@marketpublishers.com

Bladder

Brain

Breast

Cervix

Gut

Kidney

Leukaemia

Liver

Lung.

Our study also discusses products in development for these cancers:

Lymphoma

Multiple myeloma

Ovary

Pancreas

Prostate

Sarcoma and skin

Stomach

Other cancers.

R&D in oncology holds strength, variety, and promise. You assess innovations, hearing

+44 20 8123 2220
info@marketpublishers.com

about developments and finding their significance. Discover progress.

For large companies and specialty pharma firms there exist many opportunities. Our study explains, discussing issues to help your work. Also, see what shapes the market from 2013.

What affects the industry and market for anti-cancer drugs?

Our report discusses issues and events affecting that industry and market from 2013, including these:

- Epidemiology - incidence, prevalence, mortality, and survival
- Tumour (tumor) resistance, heterogeneity, and other medical challenges
- Personalised medicine, live licensing, and theranostics
- Cost-effectiveness, pricing, and reimbursement
- Payers and healthcare policy.

The study also discusses other aspects of cancer treatment, including these:

- Monoclonal antibodies (mAbs), cancer vaccines, and other technologies
- Efficacy, toxicity, and alternative treatments
- Biosimilars (follow-on-protein products) and generics
- Pharmacogenomics and genome screening
- Biomarkers and diagnostics.

That way, you explore technological, economic, social, and political (STEP) questions, assessing outlooks for the business. You also analyse the anti-cancer drug industry's strengths, weaknesses, opportunities, and threats (SWOT).

+44 20 8123 2220
info@marketpublishers.com

See, then, what the future holds.

Leading companies in cancer treatment and 2017 market value

From 2013, new treatments hold great potential for investment, technological advances and high revenues. Our report predicts the world market for anti-cancer agents will reach $116.5bn in 2017, and expand further to 2023.

Our analyses show you what technologies, products, and organisations hold greatest potential. They cover these leading companies, among others:

Roche

Novartis

Celgene

AstraZeneca

Eli Lilly

Merck & Co.

Prospects for R&D in oncology are strong, and from 2013 there will arise many opportunities. Our work shows you possibilities, helping you stay ahead.

Nine ways Leading Anti-Cancer Drugs and Associated Market 2013-2023 helps you

In particular, then, our investigation gives you the following knowledge:

Revenue to 2023 for the world anti-cancer drugs market - discover that industry's overall sales potential

Revenues to 2023 for 4 world-level submarkets - investigate the potential of its components, finding the most promising places for investments and revenues

Revenues to 2023 for 25 leading products - find sales outlooks for top brands,

+44 20 8123 2220
info@marketpublishers.com

seeing how they can compete and succeed

Forecasts to 2023 for 11 leading national markets in the Americas, Europe, and Asia - discover the best countries for revenues and potential growth

Assessments of leading companies - hear about participants' activities, capabilities, results, and outlooks

Review of R&D in oncology - explore progress in research and development, finding technological and clinical possibilities

Interviews with authorities in the field - discover debates and opinions to help you stay ahead

Analysis of what stimulates and restrains that industry and market - assess challenges and strengths, helping you compete and get advantages

Competition and opportunities - investigate what shapes that market's future, including ways to develop business.

You gain information found nowhere else

That work gives independent analysis. You receive business intelligence found only in our report, seeing where prospects are most rewarding.

With our study you are less likely to fall behind in knowledge or miss opportunity. See there how you could benefit your research, analyses, and decisions, also saving time.

Discover potential now in anti-cancer medicines and see what you can gain.

Ordering now lets you discover opportunities and predictions for cancer treatments

Our new study is for everyone analysing the industry and market for pharmaceutical biotechnology and cancer medicines. There you find data, trends, opportunities, and predictions. Avoid missing out - please order our report now.

+44 20 8123 2220
info@marketpublishers.com

Contents

+44 20 8123 2220
info@marketpublishers.com

+44 20 8123 2220
info@marketpublishers.com

+44 20 8123 2220
info@marketpublishers.com

+44 20 8123 2220
info@marketpublishers.com

+44 20 8123 2220
info@marketpublishers.com

7. LEADING COMPANIES FOR CANCER TREATMENTS, 2013

8. R&D PIPELINES FOR CANCER TREATMENT

+44 20 8123 2220
info@marketpublishers.com

9. SWOT AND STEP ANALYSES, 2013

+44 20 8123 2220
info@marketpublishers.com

10. RESEARCH INTERVIEWS

+44 20 8123 2220
info@marketpublishers.com

11. CONCLUSIONS

+44 20 8123 2220
info@marketpublishers.com

List Of Tables

LIST OF TABLES

+44 20 8123 2220
info@marketpublishers.com

+44 20 8123 2220
info@marketpublishers.com

+44 20 8123 2220
info@marketpublishers.com

+44 20 8123 2220
info@marketpublishers.com

About

Afinitor (Novartis) – A Breast Cancer Breakthrough

Afinitor (everolimus) is an anti-neoplastic drug that targets the mTOR protein, which is a type of protein kinase that has a role to play in cellular proliferation and the growth of blood vessels. By blocking the action of mTOR, Afinitor prevents the growth of tumours and the blood vessels that supply them. It has been approved to treat post-menopausal women with Hormone Receptor+/HER2- advanced breast cancer. In addition, it is also used to treat metastatic pancreatic neuroendocrine tumours where the cells are well differentiated. Lastly, it is used to treat RCC in patients who have been previously treated with VEGF-targeting medicines, such as Avastin,Votrient or Sutent.

Afinitor Sales, 2012 – Another Success

Afinitor's sales in 2012 were $0.8bn, which is represents an increase of 81.82% over the 2011 sales figure of $0.44bn. Sales were driven primarily by approval in the US and EU for the most common form of advanced breast cancer, HR+/HER2- advanced breast cancer. Table 5.42 and Figure 5.20 show Afinitor's sales from 2011.

Competition Facing Afinitor

Afinitor faces competition from a number of products, such as these:

Torisel (Pfizer): $0.37bn in sales in 2012

Nexavar (Bayer/Onyx Pharmaceuticals): $1.02bn in sales in 2012.

Visiongain expects Afinitor to perform well over the forecast period because it was recently approved for the most common type of breast cancer, in both the US and EU, which afflicts 220,000 women annually. In addition, Afinitor is the first major breakthrough in the treatment of this disease for 15 years.

Afinitor's first patents begin to expire in the US in 2016, and so generic competition will only become established after this date. In addition, since Afinitor is a conventional pharmaceutical product and not a biologic, visiongain expects it to come under severe pressure from generic alternatives not long after the expiry of its patents.

+44 20 8123 2220
info@marketpublishers.com

I would like to order

Product name: Leading Anti-Cancer Drugs and Associated Market 2013-2023
Product link: https://marketpublishers.com/r/LA0F1D356C7EN.html
Price: US$ 2,635.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:
info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page https://marketpublishers.com/r/LA0F1D356C7EN.html

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

**All fields are required

Custumer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at https://marketpublishers.com/docs/terms.html

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970